DOI: http://dx.doi.org/10.18203/2349-3933.ijam20190125

Treatment outcome of multiple myeloma (MM) based on cytogenetic risk stratification: a single institute experience from south India

Guruprasad Bhat

Abstract


Background: To study the epidemiology, incidence and the clinical outcome of multiple myeloma (MM) among the patients based on the cytogenetic risk stratification.

Methods: Author retrospectively analysed 50 patients of Multiple Myeloma (MM) with conventional cytogenetics and interphase Fluorescence In-Situ Hybridization (FISH) method and author classified the risk on the mSMART classification. Treatment and outcome were evaluated separately based on the cytogenetic risk stratification for three arms of treatment- Bortezomib, Thalidomide and Dexamethasone (BTD), Thalidomide and Dexamethasone (TD) and Lenalidomide and Dexamethasone (LD).

Results: The median age of the patients was 61years (48-74years) and ratio between male to female was 1.5:1. The overall response (OR) rate among high risk patients treated with Bortezomib, Thalidomide and Dexamethasone (BTD) was 100% with Complete Response (CR) being 26.7%. The OR rate and CR rates among standard risk treated with Thalidomide and Dexamethasone (TD) and Lenalidomide and Dexamethasone (LD) were 61%, 11% and 76%, 18% respectively. The two years overall survival (OS) was 53.3% in high risk and 66.7% with Thalidomide and Dexamethasone (TD) and 76.5% with Lenalidomide and Dexamethasone (LD) in low risk group.

Conclusions: The present study showed that the high-risk features of cytogenetics portend poor outcome among MM patients. Bortezomib, Thalidomide and Dexamethasone (BTD) based therapy have improved the Overall Response (OR) rate and Complete Response (CR) rates in high risk MM, however overall survival (OS) is poor in this risk strata. The study also showed that cytogenetic risk stratification and the outcome of myeloma do correlated with each other.

Keywords


Bortezomib, Cytogenetics, Dexamethasone, Multiple myeloma, Thalidomide

Full Text:

PDF

References


Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. Cancer statistics. Cancer J Clin. 2009;59(4):225-49.

Nair MK, Varghese C, Krishnan E, Sankaranarayanan R, Nair BA. Survival in multiple myeloma in Kerala. National Med J India. 1993;6(1):7-10.

Kumar LA, Vikram P, Kochupillai V. Recent advances in the management of multiple myeloma. National Med J India. 2006;19(2):80.

Dispenzieri A, Rajkumar SV, Gertz MA, Lacy MQ, Kyle RA, Greipp PR, et al. Treatment of newly diagnosed multiple myeloma based on mayo stratification of myeloma and risk-adapted therapy (msmart): consensus statement. In: Mayo Clinic Proceedings. Elsevier. 2007;82(3):323-341.

Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467.

Agarwal N, Kumar P, Rai M, Singh RG, Seth M, Saraf SK. Myeloma in young age. Ind J Pathol Microbiol. 2005;48(3):314-7.

Decaux O, Lodé L, Magrangeas F, Charbonnel C, Gouraud W, Jézéquel P, et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome. J Clin Oncol. 2008;26(29):4798-805.

Sawyer JR, Waldron JA, Jagannath S, Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Gen Cytogen. 1995;82(1):41-9.

Dimopoulos MA, Terpos E. Multiple myeloma. Ann Oncol.2010: 21(7):143-50.

Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol. 2002;20(21):4319-23.

Verma R, Kumar L, Gupta R, Halder A, Sharma A, Saxena R. Impact of cytogenetics on clinical outcome in multiple myeloma: a risk stratification model. J Clin Oncol. 2011;29:e18576.

Cavo M, Pantani L, Petrucci MT, Patriarca F, Zamagni E, Donnarumma D, et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma. Blood. 2012:9.

Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol. 2003;21(1):16-9.

Jacobus SJ, Kumar S, Uno H, Van Wier SA, Ahmann GJ, Henderson KJ, et al. Impact of high‐risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03. Brit J Haematol. 2011;155(3):340-8.

Rosiñol L, Oriol A, Teruel AI, Hernández D, López-Jiménez J, de la Rubia J, et al. Superiority of bortezomib, thalidomide and dexamethasone (VTD) as induction pre-transplantation therapy in multiple myeloma: a randomized phase III PETHEMA/GEM study. Blood. 2012:1589-96.

Bergsagel PL, Mateos MV, Gutierrez NC, Rajkumar SV, San Miguel JF. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood. 2013;121(6):884-92.

San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. New Eng J Med. 2008;359(9):906-17.

Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood. 2008;112(5):1593-9.

Palumbo A, Falco P, Falcone A, Benevolo G, Canepa L, Gay F, et al. Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results. Clin Lymph Myel. 2009;9(2):145-50.